1

Cannabis Production Amendments

2025 GENERAL SESSION

STATE OF UTAH

Chief Sponsor: Paul A. Cutler

Senate Sponsor: Evan J. Vickers

LONG TITLE
General Description:
This bill amends provisions related to medical cannabis production.
Highlighted Provisions:
This bill:
• requires cannabis production establishments to include in their operating plan methods to
reduce odor;
 creates requirements regarding tenancy and certain cannabis production establishments;
 requires the Department of Agriculture and Food to create recommendations for odor
control; and
 amends provisions related to land use for medical cannabis production establishments.
Money Appropriated in this Bill:
None
Other Special Clauses:
None
Utah Code Sections Affected:
AMENDS:
4-41a-204, as last amended by Laws of Utah 2023, Chapter 327
4-41a-406, as last amended by Laws of Utah 2024, Chapter 238
26B-1-310, as last amended by Laws of Utah 2023, Chapters 273, 281 and renumbered
and amended by Laws of Utah 2023, Chapter 305 and last amended by Coordination Clause,
Laws of Utah 2023, Chapter 305
ENACTS:
4-41a-204.1 , Utah Code Annotated 1953

30 **4-41a-204**. Operating plan.

31	(1) A person applying for a cannabis production establishment license or license renewal
32	shall submit to the department for the department's review a proposed operating plan
33	that complies with this section and that includes:
34	(a) a description of the physical characteristics of the proposed facility or, for a cannabis
35	cultivation facility, no more than two facility locations, including a floor plan and an
36	architectural elevation;
37	(b) a description of the credentials and experience of:
38	(i) each officer, director, and owner of the proposed cannabis production
39	establishment; and
40	(ii) any highly skilled or experienced prospective employee;
41	(c) the cannabis production establishment's employee training standards;
42	(d) a security plan;
43	(e) a description of the cannabis production establishment's inventory control system,
44	including a description of how the inventory control system is compatible with the
45	state electronic verification system described in Section 26B-4-202;
46	(f) storage protocols, both short- and long-term, to ensure that cannabis is stored in a
47	manner that is sanitary and preserves the integrity of the cannabis;
48	(g) for a cannabis cultivation facility, the information described in Subsection (2);
49	(h) for a cannabis processing facility, the information described in Subsection (3); [and]
50	(i) for an independent cannabis testing laboratory, the information described in
51	Subsection (4)[-] <u>; and</u>
52	(j) for a cannabis production establishment located in an industrial zone, a plan to reduce
53	odor created by the cannabis production establishment that:
54	(i) meets local ordinance nuisance laws; and
55	(ii) identifies:
56	(A) operations and materials that generate odors; and
57	(B) equipment, operations, or materials the cannabis production establishment will
58	use to mitigate odor emissions, including plans to maintain equipment.
59	(2)(a) A cannabis cultivation facility shall ensure that the facility's operating plan
60	includes the facility's intended:
61	(i) cannabis cultivation practices, including the facility's intended pesticide use and
62	fertilizer use; and
63	(ii) subject to Subsection (2)(b), acreage or square footage under cultivation and
64	anticipated cannabis yield.

65	(b) Except as provided in Subsection (2)(c)(i) or (c)(ii), a cannabis cultivation facility
66	may not:
67	(i) for a facility that cultivates cannabis only indoors, use more than 100,000 total
68	square feet of cultivation space;
69	(ii) for a facility that cultivates cannabis only outdoors, use more than four acres for
70	cultivation; and
71	(iii) for a facility that cultivates cannabis through a combination of indoor and
72	outdoor cultivation, use more combined indoor square footage and outdoor
73	acreage than allowed under the department's formula described in Subsection
74	(2)(e).
75	(c)(i) Each licensee may apply to the department for:
76	(A) a one-time, permanent increase of up to 20% of the limitation on the cannabis
77	cultivation facility's cultivation space; or
78	(B) a short-term increase, not to exceed 12 months, of up to 40% of the limitation
79	on the cannabis cultivation facility's cultivation space.
80	(ii) After conducting a review equivalent to the review described in Subsection
81	4-41a-205(2)(a), if the department determines that additional cultivation is
82	needed, the department may:
83	(A) grant the one-time, permanent increase described in Subsection $(2)(c)(i)(A)$; or
84	(B) grant the short-term increase described in Subsection $(2)(c)(i)(B)$.
85	(d) If a licensee describes an intended acreage or square footage under cultivation under
86	Subsection (2)(a)(ii) that is less than the limitation described in Subsection (2)(b), the
87	licensee may not cultivate more than the licensee's identified intended acreage or
88	square footage under cultivation.
89	(e) The department shall, in accordance with Title 63G, Chapter 3, Utah Administrative
90	Rulemaking Act, establish a formula for combined usage of indoor and outdoor
91	cultivation that:
92	(i) does not exceed, in estimated cultivation yield, the aggregate limitations described
93	in Subsection (2)(b)(i) or (ii); and
94	(ii) allows a cannabis cultivation facility to operate both indoors and outdoors.
95	(f)(i) The department may authorize a cannabis cultivation facility to operate at no
96	more than two separate locations.
97	(ii) If the department authorizes multiple locations under Subsection (2)(f)(i), the two
98	cannabis cultivation facility locations combined may not exceed the cultivation

99	limitations described in this Subsection (2).
100	(3) A cannabis processing facility's operating plan shall include the facility's intended
101	cannabis processing practices, including the cannabis processing facility's intended:
102	(a) offered variety of cannabis product;
103	(b) cannabinoid extraction method;
104	(c) cannabinoid extraction equipment;
105	(d) processing equipment;
106	(e) processing techniques; and
107	(f) sanitation and manufacturing safety procedures for items for human consumption.
108	(4) An independent cannabis testing laboratory's operating plan shall include the
109	laboratory's intended:
110	(a) cannabis and cannabis product testing capability;
111	(b) cannabis and cannabis product testing equipment; and
112	(c) testing methods, standards, practices, and procedures for testing cannabis and
113	cannabis products.
114	(5) Notwithstanding an applicant's proposed operating plan, a cannabis production
115	establishment is subject to land use regulations, as defined in Sections 10-9a-103 and
116	17-27a-103, regarding the availability of outdoor cultivation in an industrial zone.
117	$\hat{H} \rightarrow [\underline{(6)(a)}]$ Unless otherwise permitted by local ordinance, an indoor cannabis production
118	establishment:
119	[(i) shall be located in a stand-alone building; and]
120	[(ii) may not be located in a stand-alone building that has other tenants located in the
121	building unless the other tenant is a cannabis production establishment or a
122	cannabinoid processor as that term is defined in Section 4-41-102.]
123	[(b) Subsection (6)(a) does not apply to a cannabis production establishment that:]
124	[(i) as of May 7, 2025, is located in a building with other tenants;]
125	[(ii) continuously remains in the same building described in Subsection (6)(b)(i); and]
126	[(iii) has not entered into a lease agreement to become the sole tenant of the building
127	described in Subsection (6)(b)(i).] ←Ĥ
128	Section 2. Section 4-41a-204.1 is enacted to read:
129	<u>4-41a-204.1</u> . Odor control recommendations.
130	(1) As used in this section, "objectionable odor" means pollution of the ambient air beyond
131	the property line of a facility consisting of an odor that, considering the odor's
132	characteristics, intensity, frequency, and duration:

133	(a) is, or can reasonably be expected to be, injurious to public health or welfare; or
134	(b) unreasonably interferes with the enjoyment of life or the use of a person's property
135	that is exposed to the odor.
136	(2)(a) Before January 1, 2026, the department shall provide a report with
137	recommendations to the Medical Cannabis Governance Structure Working Group
138	created in Section 36-12-8.2 regarding objectionable odor control standards for
139	cannabis production establishments.
140	(b) <u>The department shall</u> $\hat{\mathbf{H}} \rightarrow :$
140a	(i) $\leftarrow \hat{H}$ work with a cannabis production establishment to monitor odor
141	emitted by the cannabis production establishment $\hat{\mathbf{H}} \rightarrow [\underline{\cdot}]$; and
141a	(ii) consult with each county and municipality that currently has a cannabis
141b	production establishment sited within the county or municipality's boundaries
141c	regarding potential standards for the maximum amounts of objectionable odors
141d	<u>emitted by a cannabis production establishment.</u> ←Ĥ
142	(c) A cannabis production establishment shall provide information related to the
143	cannabis production establishment's odor emissions to the department upon request.
144	(d) The report shall include an analysis regarding:
145	(i) potential standards for measurement of objectionable odors related to cannabis
146	production and distinct levels of odor tolerability;
147	(ii) the feasibility of setting a universal odor control standard;
148	(iii) the feasibility of enforcing odor control standards;
149	(iv) cost incurred by a cannabis production establishment to comply with potential
150	odor control standards;
151	(v) interests of other businesses and community members affected by objectionable
152	odor; and
153	(vi) other information the department deems relevant.
154	(3) The department shall examine odor control regulation from other locales.
155	(4) The department may collaborate with other state agencies when creating the
156	recommendations.
157	Section 3. Section 4-41a-406 is amended to read:
158	4-41a-406 . Local control.
159	(1) As used in this section:
160	(a) "Cannabis production establishment" means the same as that term is defined in
161	Section 4-41a-102 and includes a closed-door medical cannabis pharmacy.

H.B. 343

162	(b) "Land use application" means the same as that term is defined in Sections 10-9a-103
163	and 17-27a-103.
164	[(b)] (c) "Land use decision" means the same as that term is defined in Sections
165	10-9a-103 and 17-27a-103.
166	[(c)] (d) "Land use permit" means the same as that term is defined in Sections 10-9a-103
167	and 17-27a-103.
168	[(d)] (e) "Land use regulation" means the same as that term is defined in Sections
169	10-9a-103 and 17-27a-103.
170	(2)(a) If a municipality's or county's zoning ordinances provide for an industrial zone,
171	the operation of a cannabis production establishment shall be a permitted industrial
172	use in any industrial zone unless the municipality or county has designated by
173	ordinance $\hat{H} \rightarrow [\{] \leftarrow \hat{H}$, before an individual submits a land use permit application for
173a	a cannabis
174	production establishment, $\hat{H} \rightarrow [] \leftarrow \hat{H}$ at least one industrial zone in which the operation of a
175	cannabis production establishment is a permitted use.
176	(b) If a municipality's or county's zoning ordinances provide for an agricultural zone, the
177	operation of a cannabis production establishment shall be a permitted agricultural use
178	in any agricultural zone unless the municipality or county has designated by
	ordinance Ĥ→ [[] ←Ĥ
179	, before an individual submits a land use permit application for a cannabis production
180	establishment, $\hat{H} \rightarrow [] \rightarrow \hat{H}$ at least one agricultural zone in which the operation of a cannabis
181	production establishment is a permitted use.
182	(c) The operation of a cannabis production establishment shall be a permitted use on
183	land that the municipality or county has not zoned.
184	(3) A municipality or county may not:
185	(a) on the sole basis that the applicant, or cannabis production establishment violates
186	federal law regarding the legal status of cannabis, deny or revoke:
187	(i) a land use permit to operate a cannabis production facility; or
188	(ii) a business license to operate a cannabis production facility; or
189	(b) require a certain distance between a cannabis production establishment and:
190	(i) another cannabis production establishment;
191	(ii) a medical cannabis pharmacy;
192	(iii) a retail tobacco specialty business, as that term is defined in Section 26B-7-501;
193	or

101	
194	(iv) an outlet, as that term is defined in Section 32B-1-202[; or].
195	[(c) in accordance with Subsections 10-9a-509(1) and 17-27a-508(1), enforce a land use
196	regulation against a cannabis production establishment that was not in effect on the
197	day on which the cannabis production establishment submitted a complete land use
198	application.]
199	(4)(a) Subject to the provisions of this section, when evaluating and approving a land
200	use application for a cannabis production establishment:
201	(i) a municipality shall comply with Section 10-9a-509; and
202	(ii) a county shall comply with Section 17-27a-508.
203	(b) An applicant for a land use permit to operate a cannabis production establishment
204	shall comply with the land use requirements and application process described in:
205	[(a)] (i) Title 10, Chapter 9a, Municipal Land Use, Development, and Management
206	Act[, including Section 10-9a-528]; and
207	[(b)] (ii) Title 17, Chapter 27a, County Land Use, Development, and Management Act[
208	, including Section 17-27a-525].
209	Section 4. Section 26B-1-310 is amended to read:
210	26B-1-310 . Qualified Patient Enterprise Fund Creation Revenue neutrality
210	20D-1-510. Quanteu l'attent Enterprise l'unu creation Révenue neutranty
210	Uniform fee.
211	Uniform fee.
211 212	 Uniform fee.(1) There is created an enterprise fund known as the "Qualified Patient Enterprise Fund."
211 212 213	 Uniform fee. (1) There is created an enterprise fund known as the "Qualified Patient Enterprise Fund." (2) The fund created in this section is funded from:
211 212 213 214	 Uniform fee. (1) There is created an enterprise fund known as the "Qualified Patient Enterprise Fund." (2) The fund created in this section is funded from: (a) money the department deposits into the fund under Chapter 4, Part 2, Cannabinoid
 211 212 213 214 215 	 Uniform fee. (1) There is created an enterprise fund known as the "Qualified Patient Enterprise Fund." (2) The fund created in this section is funded from: (a) money the department deposits into the fund under Chapter 4, Part 2, Cannabinoid Research and Medical Cannabis;
 211 212 213 214 215 216 	 Uniform fee. (1) There is created an enterprise fund known as the "Qualified Patient Enterprise Fund." (2) The fund created in this section is funded from: (a) money the department deposits into the fund under Chapter 4, Part 2, Cannabinoid Research and Medical Cannabis; (b) appropriations the Legislature makes to the fund; and
 211 212 213 214 215 216 217 	 Uniform fee. (1) There is created an enterprise fund known as the "Qualified Patient Enterprise Fund." (2) The fund created in this section is funded from: (a) money the department deposits into the fund under Chapter 4, Part 2, Cannabinoid Research and Medical Cannabis; (b) appropriations the Legislature makes to the fund; and (c) the interest described in Subsection (3).
 211 212 213 214 215 216 217 218 	 Uniform fee. (1) There is created an enterprise fund known as the "Qualified Patient Enterprise Fund." (2) The fund created in this section is funded from: (a) money the department deposits into the fund under Chapter 4, Part 2, Cannabinoid Research and Medical Cannabis; (b) appropriations the Legislature makes to the fund; and (c) the interest described in Subsection (3). (3) Interest earned on the fund shall be deposited into the fund.
 211 212 213 214 215 216 217 218 219 	 Uniform fee. (1) There is created an enterprise fund known as the "Qualified Patient Enterprise Fund." (2) The fund created in this section is funded from: (a) money the department deposits into the fund under Chapter 4, Part 2, Cannabinoid Research and Medical Cannabis; (b) appropriations the Legislature makes to the fund; and (c) the interest described in Subsection (3). (3) Interest earned on the fund shall be deposited into the fund. (4) Money deposited into the fund may only be used by:
 211 212 213 214 215 216 217 218 219 220 	 Uniform fee. (1) There is created an enterprise fund known as the "Qualified Patient Enterprise Fund." (2) The fund created in this section is funded from: (a) money the department deposits into the fund under Chapter 4, Part 2, Cannabinoid Research and Medical Cannabis; (b) appropriations the Legislature makes to the fund; and (c) the interest described in Subsection (3). (3) Interest earned on the fund shall be deposited into the fund. (4) Money deposited into the fund may only be used by: (a) the department to accomplish the department's responsibilities described in Chapter
 211 212 213 214 215 216 217 218 219 220 221 	 Uniform fee. (1) There is created an enterprise fund known as the "Qualified Patient Enterprise Fund." (2) The fund created in this section is funded from: (a) money the department deposits into the fund under Chapter 4, Part 2, Cannabinoid Research and Medical Cannabis; (b) appropriations the Legislature makes to the fund; and (c) the interest described in Subsection (3). (3) Interest earned on the fund shall be deposited into the fund. (4) Money deposited into the fund may only be used by: (a) the department to accomplish the department's responsibilities described in Chapter 4, Part 2, Cannabinoid Research and Medical Cannabis; [and]
 211 212 213 214 215 216 217 218 219 220 221 222 	 Uniform fee. (1) There is created an enterprise fund known as the "Qualified Patient Enterprise Fund." (2) The fund created in this section is funded from: (a) money the department deposits into the fund under Chapter 4, Part 2, Cannabinoid Research and Medical Cannabis; (b) appropriations the Legislature makes to the fund; and (c) the interest described in Subsection (3). (3) Interest earned on the fund shall be deposited into the fund. (4) Money deposited into the fund may only be used by: (a) the department to accomplish the department's responsibilities described in Chapter 4, Part 2, Cannabinoid Research and Medical Cannabis; [and] (b) the Center for Medical Cannabis Research created in Section 53B-17-1402 to
 211 212 213 214 215 216 217 218 219 220 221 222 223 	 Uniform fee. (1) There is created an enterprise fund known as the "Qualified Patient Enterprise Fund." (2) The fund created in this section is funded from: (a) money the department deposits into the fund under Chapter 4, Part 2, Cannabinoid Research and Medical Cannabis; (b) appropriations the Legislature makes to the fund; and (c) the interest described in Subsection (3). (3) Interest earned on the fund shall be deposited into the fund. (4) Money deposited into the fund may only be used by: (a) the department to accomplish the department's responsibilities described in Chapter 4, Part 2, Cannabinoid Research and Medical Cannabis; [and] (b) the Center for Medical Cannabis Research 's responsibilities[:] : and
 211 212 213 214 215 216 217 218 219 220 221 222 223 224 	 Uniform fee. (1) There is created an enterprise fund known as the "Qualified Patient Enterprise Fund." (2) The fund created in this section is funded from: (a) money the department deposits into the fund under Chapter 4, Part 2, Cannabinoid Research and Medical Cannabis; (b) appropriations the Legislature makes to the fund; and (c) the interest described in Subsection (3). (3) Interest earned on the fund shall be deposited into the fund. (4) Money deposited into the fund may only be used by: (a) the department to accomplish the department's responsibilities described in Chapter 4, Part 2, Cannabinoid Research and Medical Cannabis; [and] (b) the Center for Medical Cannabis Research created in Section 53B-17-1402 to accomplish the Center for Medical Cannabis Research's responsibilities[-:] ; and (c) the Department of Agriculture and Food for the one time purchase of equipment to
 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 	 Uniform fee. (1) There is created an enterprise fund known as the "Qualified Patient Enterprise Fund." (2) The fund created in this section is funded from: (a) money the department deposits into the fund under Chapter 4, Part 2, Cannabinoid Research and Medical Cannabis; (b) appropriations the Legislature makes to the fund; and (c) the interest described in Subsection (3). (3) Interest earned on the fund shall be deposited into the fund. (4) Money deposited into the fund may only be used by: (a) the department to accomplish the department's responsibilities described in Chapter 4, Part 2, Cannabinoid Research and Medical Cannabis; [and] (b) the Center for Medical Cannabis Research created in Section 53B-17-1402 to accomplish the Center for Medical Cannabis Research's responsibilities[-]; and (c) the Department of Agriculture and Food for the one time purchase of equipment to meet the requirements described in Section 4-41a-204.1.

H.B. 343

- to cover the department's cost to implement Chapter 4, Part 2, Cannabinoid Research
- and Medical Cannabis.
- 230 (6) The department may impose a uniform fee on each medical cannabis transaction in a
- 231 medical cannabis pharmacy in an amount that, subject to Subsection (5), the department
- sets in accordance with Section 63J-1-504.
- 233 Section 5. Effective Date.
- 234 This bill takes effect on May 7, 2025.